Collection of Primary Retroperitoneal Sarcoma Data, Radiological, and Pathological Material for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

Overview

About this study

The purpose of this study is to prospectively collect standardized clinical data and radiological and pathological material from primary retroperitoneal sarcomas RPS patients treated with surgery at reference centers. Patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Primary RPS operated on in the participating center.
  • Primary RPS who undergo incomplete resection at another hospital and therefore candidate to completion surgery of persistent primary disease in the participating center.
  • Primary RPS candidate to neoadjuvant treatment in the participating center and not receiving surgery for whichever reason.
  • Age>18 years at the time of the first treatment (pediatric patients can not be included).
  • Histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist.
  • Radiological examinations performed (contrast enhanced abdominal CT scan and/or MRI) prior to surgical resection.
  • Signed informed consent form.
  • Adequate compliance of the patients to the plan of follow-up.

Exclusion Criteria:

  • Age < 18 years.
  • Recurrent tumor.
  • Benign retroperitoneal tumors.
  • Serious psychiatric disease that precludes informed consent or limits compliance.
  • Impossibility to ensure adequate follow-up.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/16/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Sanjay Bagaria, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available